JDD Article Highlight
JDD’s article titled “To Acne and Beyond: A Review of Sarecycline’s Off-Label Uses” discusses how sarecycline, a third-generation tetracycline, is FDA-approved for moderate to severe acne in patients 9 and older. It offers a narrow spectrum of activity, targeting Cutibacterium acnes with fewer effects on gut microbes, reducing the risk of antibiotic resistance and minimizing side effects like nausea and headache. Its once-daily dosing promotes adherence, and it’s shown to be as effective as older tetracyclines in treating both facial and truncal acne. Beyond acne, sarecycline is used off-label for rosacea, perioral dermatitis, and other dermatologic conditions, making it a valuable option for dermatologists managing various skin disorders.
